Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study.

Galve E, Cordero A, Cequier A, Ruiz E, González-Juanatey JR.

Rev Esp Cardiol (Engl Ed). 2016 May 10. pii: S1885-5857(16)30009-3. doi: 10.1016/j.rec.2016.02.012. [Epub ahead of print] English, Spanish.

PMID:
27178117
2.

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.

Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova-Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez-Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, Gómez-Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A.

Eur J Heart Fail. 2016 May 12. doi: 10.1002/ejhf.548. [Epub ahead of print]

PMID:
27170530
3.

[Medical expert consensus in AH on the clinical use of triple fixed-dose antihypertensive therapy in Spain].

Mazón P, Galve E, Gómez J, Gorostidi M, Górriz JL, Mediavilla JD; en representación de las Sociedades Españolas de Cardiología, Medicina Interna y Nefrología.

Hipertens Riesgo Vasc. 2016 Apr 26. pii: S1889-1837(16)30005-8. doi: 10.1016/j.hipert.2016.03.001. [Epub ahead of print] Spanish.

PMID:
27129628
4.

[Consensus on objectives and action guidelines on low density lipoproteins-cholesterol control in very high risk cardiovascular patients].

Galve E, Guijarro-Herraiz C, Masana-Marin L, Cordero-Fort A.

Clin Investig Arterioscler. 2016 Jan-Feb;28(1):31-42. doi: 10.1016/j.arteri.2015.09.002. Epub 2015 Dec 3. Spanish.

PMID:
26657097
5.

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I, Olier C, Fernández-Aramburo A, Llorca C, González X, Llorente R, Torregrosa D, Álvarez I, Gálve E, Bueno C, Garau I, García MJ, González-Santiago S, Ballesteros AI, Blanco E, Galán A, González S, Perelló A, Cortés-Funes H, Grávalos C.

Anticancer Res. 2015 Dec;35(12):6941-50.

PMID:
26637920
6.

Trends in Risk Factors and Treatments in Patients With Stable Ischemic Heart Disease Seen at Cardiology Clinics Between 2006 and 2014.

Cordero A, Galve E, Bertomeu-Martínez V, Bueno H, Fácila L, Alegría E, Cequier Á, Ruiz E, González-Juanatey JR.

Rev Esp Cardiol (Engl Ed). 2016 Apr;69(4):401-7. doi: 10.1016/j.rec.2015.08.011. Epub 2015 Nov 27.

PMID:
26631917
7.

Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC.

Gómez Huelgas R, Gómez Peralta F, Carrillo Fernández L, Galve E, Casanueva FF, Puig Domingo M, Mediavilla Bravo JJ, Orozco Beltrán D; en nombre del Grupo de Trabajo para el Documento de Consenso «Hacia un manejo integral del paciente con diabetes y obesidad», Muñoz JE, Menéndez Torre E, Artola Menendez S, Mazón Ramos P, Monereo Megías S, Caixas Pedrágos A, López Simarro F, Álvarez Guisasola F.

Rev Clin Esp. 2015 Dec;215(9):505-14. doi: 10.1016/j.rce.2015.07.003. Epub 2015 Sep 9. English, Spanish.

PMID:
26363771
8.

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M.

Curr Cancer Drug Targets. 2016;16(5):415-28. Review.

PMID:
26278712
9.

[Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines].

Lobos Bejarano JM, Galve E, Royo-Bordonada MÁ, Alegría Ezquerra E, Armario P, Brotons Cuixart C, Camafort Babkowski M, Cordero Fort A, Maiques Galán A, Mantilla Morató T, Pérez Pérez A, Pedro-Botet J, Villar Álvarez F, González-Juanatey JR; Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology.

Hipertens Riesgo Vasc. 2015 Apr-Jun;32(2):83-91. doi: 10.1016/j.hipert.2014.09.002. Epub 2014 Nov 14. Spanish.

PMID:
26179969
10.

[Changing the paradigm: valsartan-inhibitor of neprilysin, a new dual-acting drug for arterial hypertension and heart failure].

Galve E, Casas-Masnou G, García-Dorado D.

Hipertens Riesgo Vasc. 2015 Jan-Mar;32(1):1-5. doi: 10.1016/j.hipert.2014.11.001. Epub 2014 Dec 15. Spanish. No abstract available.

PMID:
26179851
11.

Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management: differences between the European and American Guidelines.

Lobos Bejarano JM, Galve E, Royo-Bordonada MÁ, Alegría Ezquerra E, Armario P, Brotons Cuixart C, Camafort Babkowski M, Cordero Fort A, Maiques Galán A, Mantilla Morató T, Pérez Pérez A, Pedro-Botet J, Villar Álvarez F, González-Juanatey JR; Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention; Spanish Society of Cardiology.

Rev Esp Salud Publica. 2015 Jan-Feb;89(1):15-26. doi: 10.4321/S1135-57272015000100003. English, Spanish.

12.

Importance of sudden cardiac death risk stratification in hypertrophic cardiomyopathy. Response.

Sarrias A, Galve E, Sabaté X, Villuendas R.

Rev Esp Cardiol (Engl Ed). 2015 Jun;68(6):545. doi: 10.1016/j.rec.2015.02.007. Epub 2015 Apr 20. No abstract available.

PMID:
25907859
13.

[Renal denervation as treatment of resistant hypertension].

Galve E, Martell-Claros N, Camafort-Babkowski M; Grupo de consenso español sobre denervación renal.

Med Clin (Barc). 2015 Aug 7;145(3):131-5. doi: 10.1016/j.medcli.2014.12.011. Epub 2015 Mar 4. Spanish. No abstract available.

PMID:
25746610
14.

Update in cardiology: vascular risk and cardiac rehabilitation.

Galve E, Cordero A, Bertomeu-Martínez V, Fácila L, Mazón P, Alegría E, Fernández de Bobadilla J, García-Porrero E, Martínez-Sellés M, González-Juanatey JR.

Rev Esp Cardiol (Engl Ed). 2015 Feb;68(2):136-43. doi: 10.1016/j.rec.2014.10.005. Epub 2015 Jan 9.

PMID:
25583549
15.

Comments on the 2014 ESC Guidelines on the diagnosis and management of hypertrophic cardiomyopathy. A critical view from the perspective of Spanish cardiology.

SEC Working Group for the 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy; Expert Reviewers for the ESC 2014 Guidelines on the Diagnosis and Management of Hypertrophic Cardiomyopathy; SEC Clinical Practice Guidelines Committee.

Rev Esp Cardiol (Engl Ed). 2015 Jan;68(1):4-9. doi: 10.1016/j.rec.2014.10.011. No abstract available.

PMID:
25553935
16.

[Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].

Lobos Bejarano JM, Galve E, Royo-Bordonada MÁ, Alegría Ezquerra E, Armario P, Brotons Cuixart C, Camafort Babkowski M, Cordero Fort A, Maiques Galán A, Mantilla Morató T, Pérez Pérez A, Pedro-Botet J, Villar Álvarez F, González-Juanatey JR; en nombre del Comité Español Interdisciplinario de Prevención Cardiovascular y de la Sociedad Española de Cardiología.

Semergen. 2015 Apr;41(3):149-57. doi: 10.1016/j.semerg.2014.05.020. Epub 2014 Nov 14. Spanish.

PMID:
25450438
17.

Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention.

Sarrias A, Galve E, Sabaté X, Moya À, Anguera I, Núñez E, Villuendas R, Alcalde Ó, García-Dorado D.

Rev Esp Cardiol (Engl Ed). 2015 Jun;68(6):492-6. doi: 10.1016/j.rec.2014.06.025. Epub 2014 Nov 20.

PMID:
25449813
18.

[Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines].

Lobos Bejarano JM, Galve E, Royo-Bordonada MÁ, Alegría Ezquerra E, Armario P, Brotons Cuixart C, Camafort Babkowski M, Cordero Fort A, Maiques Galán A, Mantilla Morató T, Pérez Pérez A, Pedro-Botet J, Villar Álvarez F, González-Juanatey JR; Comité Español Interdisciplinario de Prevención Cardiovascular y de la Sociedad Española de Cardiología.

Clin Investig Arterioscler. 2015 Jan-Feb;27(1):36-44. doi: 10.1016/j.arteri.2014.09.001. Epub 2014 Nov 14. Spanish.

PMID:
25444651
19.

Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines.

Lobos Bejarano JM, Galve E, Royo-Bordonada MÁ, Alegría Ezquerra E, Armario P, Brotons Cuixart C, Camafort Babkowski M, Cordero Fort A, Maiques Galán A, Mantilla Morató T, Pérez Pérez A, Pedro-Botet J, Villar Álvarez F, González-Juanatey JR; Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention; Spanish Society of Cardiology.

Rev Esp Cardiol (Engl Ed). 2014 Nov;67(11):913-9. doi: 10.1016/j.rec.2014.05.008. Epub 2014 Aug 3.

PMID:
25443815
20.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators.

Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk